Roman Kotlín

413 total citations
41 papers, 309 citations indexed

About

Roman Kotlín is a scholar working on Pulmonary and Respiratory Medicine, Hematology and Molecular Biology. According to data from OpenAlex, Roman Kotlín has authored 41 papers receiving a total of 309 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pulmonary and Respiratory Medicine, 21 papers in Hematology and 10 papers in Molecular Biology. Recurrent topics in Roman Kotlín's work include Blood properties and coagulation (21 papers), Platelet Disorders and Treatments (10 papers) and Acute Myeloid Leukemia Research (8 papers). Roman Kotlín is often cited by papers focused on Blood properties and coagulation (21 papers), Platelet Disorders and Treatments (10 papers) and Acute Myeloid Leukemia Research (8 papers). Roman Kotlín collaborates with scholars based in Czechia, United States and Poland. Roman Kotlín's co-authors include Jiřı́ Suttnar, Jan E. Dyr, Tomáš Riedel, Zuzana Reicheltová, Peter Salaj, Pavel Májek, Kristýna Pimková, Martin Malý, Jaroslav Čermák and John W. Weisel and has published in prestigious journals such as Blood, Analytical Chemistry and Scientific Reports.

In The Last Decade

Roman Kotlín

38 papers receiving 304 citations

Peers

Countries citing papers authored by Roman Kotlín

Since Specialization

Citations

This map shows the geographic impact of Roman Kotlín's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roman Kotlín with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roman Kotlín more than expected).

Fields of papers citing papers by Roman Kotlín

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roman Kotlín. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roman Kotlín. The network helps show where Roman Kotlín may publish in the future.

Co-authorship network of co-authors of Roman Kotlín

This figure shows the co-authorship network connecting the top 25 collaborators of Roman Kotlín. A scholar is included among the top collaborators of Roman Kotlín based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roman Kotlín. Roman Kotlín is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Structural and Functional Characterization of Four Novel Fibrinogen Mutations in FGB Causing Congenital Fibrinogen Disorder 2022 ·International Journal of Molecular Sciences ·(unknown), (unknown), Žofie Sovová, (unknown), (unknown), Roman Kotlín, Jiřı́ Suttnar	5
2	Incorporation of Fibrin, Platelets, and Red Blood Cells into a Coronary Thrombus in Time and Space 2021 ·Thrombosis and Haemostasis ·Martin Malý, Tomáš Riedel, (unknown), Jiřı́ Suttnar, Roman Kotlín, (unknown), Petr Toušek, (unknown), (unknown), John W. Weisel, Jan E. Dyr	11
3	A New Approach for the Diagnosis of Myelodysplastic Syndrome Subtypes Based on Protein Interaction Analysis 2019 ·Scientific Reports ·(unknown), (unknown), Markéta Bocková, N. Scott Lynn, Pavel Šácha, Martin Hubálek, Jiřı́ Suttnar, Roman Kotlín, (unknown), (unknown), Kristýna Pimková, Jaroslav Čermák, Jiřı́ Homola, Jan E. Dyr	8
4	Enhanced plasma protein carbonylation in patients with myelodysplastic syndromes 2017 ·Free Radical Biology and Medicine ·(unknown), (unknown), Kristýna Pimková, (unknown), Pavel Májek, Roman Kotlín, Jaroslav Čermák, Jiřı́ Suttnar, Jan E. Dyr	14
5	Abnormal Fibrinogen Zlín (γThr21Ile) with Missense Mutation Causing Hypofibrinogenemia 2014 ·Acta Haematologica ·Zuzana Reicheltová, Tomáš Riedel, Pavel Májek, Roman Kotlín, (unknown), Jiřı́ Suttnar, Jan E. Dyr	1
6	Two novel mutations in the fibrinogen γ nodule 2014 ·Thrombosis Research ·Roman Kotlín, (unknown), (unknown), (unknown), Jiřı́ Suttnar, (unknown), Tomáš Riedel, Peter Salaj, Jan E. Dyr	5
7	Plasma Levels of Aminothiols, Nitrite, Nitrate, and Malondialdehyde in Myelodysplastic Syndromes in the Context of Clinical Outcomes and as a Consequence of Iron Overload 2014 ·Oxidative Medicine and Cellular Longevity ·Kristýna Pimková, (unknown), Jiřı́ Suttnar, (unknown), Roman Kotlín, Jaroslav Čermák, Jan E. Dyr	20
8	The Effect of Reagents Mimicking Oxidative Stress on Fibrinogen Function 2013 ·The Scientific World JOURNAL ·(unknown), Roman Kotlín, Tomáš Riedel, Jiřı́ Suttnar, Kristýna Pimková, (unknown), Jan E. Dyr	33
9	Fibrinogen Šumperk II: Dysfibrinogenemia in an individual with two coding mutations 2012 ·American Journal of Hematology ·Roman Kotlín, Jiřı́ Suttnar, (unknown), Ingrid Hrachovinová, (unknown), Jan E. Dyr	10
10	CCAAT/enhancer-binding protein alpha (CEBPA) polymorphisms and mutations in healthy individuals and in patients with peripheral artery disease, ischaemic heart disease and hyperlipidaemia. 2010 ·PubMed ·Ota Fuchs, (unknown), (unknown), (unknown), Roman Kotlín, (unknown), Petr Kobylka, Gabriela Dostálová, M. Zeman, (unknown)	6
11	CCAAT/Enhancer-Binding Protein α (CEBPA) Polymorphisms and Mutations in Healthy Individuals and in Patients with Peripheral Artery Disease, Ischaemic Heart Disease and Hyperlipidaemia 2010 ·Folia Biologica ·Ota Fuchs, (unknown), (unknown), (unknown), Roman Kotlín, (unknown), Petr Kobylka, Gabriela Dostálová, M. Zeman, (unknown)	6
12	Dysfibrinogenemia in childhood: two cases of congenital dysfibrinogens 2010 ·Blood Coagulation & Fibrinolysis ·Roman Kotlín, (unknown), Jiřı́ Suttnar, Martin Malý, J Kvasnička, Jan E. Dyr	6
13	Two novel fibrinogen variants in the C-terminus of the Bβ-chain: fibrinogen Rokycany and fibrinogen Znojmo 2010 ·Journal of Thrombosis and Thrombolysis ·Roman Kotlín, Zuzana Reicheltová, Jiřı́ Suttnar, Peter Salaj, Ingrid Hrachovinová, Tomáš Riedel, Martin Malý, (unknown), J Kvasnička, Jan E. Dyr	12
14	Two cases of congenital dysfibrinogenemia associated with thrombosis – Fibrinogen Praha III and Fibrinogen Plzeň 2009 ·Thrombosis and Haemostasis ·Zuzana Reicheltová, Martin Malý, Jiřı́ Suttnar, (unknown), Peter Salaj, (unknown), Tomáš Riedel, Jan E. Dyr, Roman Kotlín	15
15	Clinical manifestation and molecular genetic characterization of MYH9 disorders 2009 ·Platelets ·(unknown), (unknown), (unknown), Roman Kotlín, (unknown), (unknown), Václav Maťoška, Ingrid Hrachovinová, (unknown)	3
16	Antioxidants change platelet responses to various stimulating events 2009 ·Free Radical Biology and Medicine ·(unknown), (unknown), Jiřı́ Suttnar, (unknown), Pavel Májek, Zuzana Reicheltová, Roman Kotlín, John W. Weisel, Martin Malý, Jan E. Dyr	36
17	Acquired Dysfibrinogenemia Secondary to Multiple Myeloma 2008 ·Acta Haematologica ·Roman Kotlín, (unknown), Tomáš Riedel, Peter Salaj, Jiřı́ Suttnar, Zuzana Reicheltová, Pavel Májek, (unknown), Jan E. Dyr	28
18	High-resolution melting analysis for detection of MYH9 mutations 2008 ·Platelets ·(unknown), (unknown), Roman Kotlín, Peter Salaj, Václav Maťoška, Ingrid Hrachovinová, (unknown)	6
19	A novel fibrinogen variant – Liberec: dysfibrinogenaemia associated with γ Tyr262Cys substitution 2008 ·European Journal Of Haematology ·Roman Kotlín, (unknown), Jiřı́ Suttnar, Peter Salaj, (unknown), Tomáš Riedel, Zuzana Reicheltová, Jan E. Dyr	9
20	Fibrinogen Nový Jičín and Praha II: Cases of hereditary Aα 16 Arg→Cys and Aα 16 Arg→His dysfibrinogenemia 2007 ·Thrombosis Research ·Roman Kotlín, (unknown), Jiřı́ Suttnar, Tomáš Riedel, Peter Salaj, Jan Blatný, Jiří Šantrůček, (unknown), Jan E. Dyr	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact